Sanofi Has One Hemophilia Winner On It Hands – But Fitusiran’s Fate Remains Unclear

Efanesoctocog Alfa Filed Last Month

 
• By Andrew McConaghie

Sanofi is hoping to have two paradigm-changing hemophilia drugs on the market by 2025 – but one of these, fitusiran, must first prove its safety and efficacy at a lower dose.

Sanofi_Berlin
Sanofi could be a major player in hemophilia within a few years - but will face competition from Roche's Hemlibra and gene therapies. • Source: Shutterstock

More from Blood and Clotting

More from Therapy Areas